We are live on ! Find out more
MNPR icon

Monopar Therapeutics
MNPR

12 hedge funds and large institutions have $310K invested in Monopar Therapeutics in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 1

16% more capital invested

Capital invested by funds: $268K → $310K (+$42K)

0.05% less ownership

Funds ownership: 0.53% → 0.48% (-0.05%)

25% less funds holding

Funds holding: 16 → 12 (-4)

80% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 5

Holders
12
Holders Change
-4
Holders Change %
-25%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
5
Reduced
1
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TSS
Two Sigma Securities
New York
+$33.1K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$13.3K
3
Millennium Management
Millennium Management
New York
+$1.35K
4
Wells Fargo
Wells Fargo
California
+$679
5
TRCT
Tower Research Capital (TRC)
New York
+$46

Top Sellers

Rank Fund Capital Flow
1
HF
HRT Financial
New York
-$21K
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$3.75K
3
VF
Virtu Financial
New York
-$3.51K
4
UBS Group
UBS Group
Switzerland
-$1.75K
5
Morgan Stanley
Morgan Stanley
New York
-$545
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
1
Millennium Management
New York
$145K +$1.35K +384 +1%
Geode Capital Management
2
Geode Capital Management
Massachusetts
$44.9K +$13.3K +3,767 +46%
TSS
3
Two Sigma Securities
New York
$34.4K +$33.1K +9,412 New
Vanguard Group
4
Vanguard Group
Pennsylvania
$33K – – –
GL
5
Gerber LLC
Ohio
$20.4K – – –
VF
6
Virtu Financial
New York
$14K -$3.51K -997 -21%
RRCM
7
Rappaport Reiches Capital Management
Illinois
$7.81K – – –
TRCT
8
Tower Research Capital (TRC)
New York
$5.78K +$46 +13 +0.8%
NA
9
NewEdge Advisors
Louisiana
$2.19K – – –
Wells Fargo
10
Wells Fargo
California
$1.82K +$679 +193 +63%
Bank of America
11
Bank of America
North Carolina
$410 +$42 +12 +12%
FDCDDQ
12
Federation des caisses Desjardins du Quebec
Quebec, Canada
$58 – – –
HF
13
HRT Financial
New York
– -$21K -6,423 Closed
Fidelity Investments
14
Fidelity Investments
Massachusetts
– -$3.75K -1,100 Closed
UBS Group
15
UBS Group
Switzerland
– -$1.75K -514 Closed
Morgan Stanley
16
Morgan Stanley
New York
– -$545 -160 Closed

MNPR Hedge Fund Activity: Q2 2024 in Review

12 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q2 2024, worth a combined $310K — up 16% from $268K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of MNPR and 1 opened new positions — a net loss of 4 holders — while 1 trimmed existing stakes and 5 added.

The largest buyer was Two Sigma Securities, opening a new position worth an estimated $33.1K. The largest seller was HRT Financial, exiting entirely with an estimated $21K sold.

  • 12 institutional investors held Monopar Therapeutics (MNPR) as of Q2 2024, down from 16 in Q1 2024.
  • Funds reported $310K of Monopar Therapeutics stock for Q2 2024, up 16% quarter-over-quarter.
  • 1 fund opened new Monopar Therapeutics positions in Q2 2024 and 5 closed out, a net change of -4 holders.
  • The largest Monopar Therapeutics buyer in Q2 2024 was Two Sigma Securities, an estimated $33.1K added.
  • The largest Monopar Therapeutics seller in Q2 2024 was HRT Financial, an estimated $21K sold.

Based on aggregated 13F filings for Q2 2024.